Pharmacovigilance of biosimilars: challenges and possible solutions

被引：4
|
作者：
Giezen, Thijs J. [1 ]
Straus, Sabine M. J. M. [2 ]
机构：
[1] Hosp Med Spectrum Twente, Clin Pharm, Postbus 50000, NL-7500 KA Enschede, Netherlands
[2] Erasmus Univ, Med Ctr, Dept Med Informat, Rotterdam, Netherlands
来源：
GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL | 2012年 / 1卷 / 3-4期
关键词：
Biologicals; biosimilars; immunogenicity; pharmacovigilance; traceability;
D O I：
10.5639/gabij.2012.0103-4.033
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Post-marketing surveillance is essential to detect, assess and prevent adverse reactions of chemically synthesized small molecule drugs as well as biologicals, as the full safety profi le can only be known after they have been placed on the market. Biologicals have specific characteristics, which pose additional challenges in pharmacovigilance.
引用
收藏
页码：118 / 119
页数：2
相关论文
共 50 条
  • [1] Pharmacovigilance and biosimilars: considerations, needs and challenges
    Casadevall, Nicole
    Edwards, I. Ralph
    Felix, Thomas
    Graze, Peter R.
    Litten, Jason B.
    Strober, Bruce E.
    Warnock, David G.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (07) : 1039 - 1047
  • [2] Pharmacovigilance of biologics and biosimilars
    Trifiro, G.
    [J]. DRUG SAFETY, 2017, 40 (10) : 1036 - 1036
  • [3] Considerations in Pharmacovigilance of Biosimilars
    Sinha, S.
    [J]. DRUG SAFETY, 2016, 39 (10) : 1029 - 1029
  • [4] Biosimilars: pharmacovigilance and risk management
    Zuniga, Leyre
    Calvo, Begona
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 (07) : 661 - 669
  • [5] Pharmacovigilance Considerations for Biosimilars in the USA
    Grampp, Gustavo
    Felix, Thomas
    [J]. BIODRUGS, 2015, 29 (05) : 309 - 321
  • [6] Comparative testing and pharmacovigilance of biosimilars
    Locatelli, Francesco
    Roger, Simon
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 13 - 16
  • [7] Pharmacovigilance Considerations for Biosimilars in the USA
    Gustavo Grampp
    Thomas Felix
    [J]. BioDrugs, 2015, 29 : 309 - 321
  • [8] Pharmacovigilance on biologicals and biosimilars: a Danish perspective
    Lunddahl, Benedicte
    [J]. GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL, 2016, 5 (03): : 123 - 124
  • [9] Barriers to the Uptake of Biosimilars and Possible Solutions: A Belgian Case Study
    Pieter Dylst
    Arnold Vulto
    Steven Simoens
    [J]. PharmacoEconomics, 2014, 32 : 681 - 691
  • [10] Barriers to the Uptake of Biosimilars and Possible Solutions: A Belgian Case Study
    Dylst, Pieter
    Vulto, Arnold
    Simoens, Steven
    [J]. PHARMACOECONOMICS, 2014, 32 (07) : 681 - 691
12345